What is the projected market valuation for the Bunya Virus Infection Market in 2035?

The projected market valuation for the Bunya Virus Infection Market in 2035 is 672.18 USD Billion. Read More

What was the overall market valuation for the Bunya Virus Infection Market in 2024?

The overall market valuation for the Bunya Virus Infection Market in 2024 was 309.02 USD Billion. Read More

What is the expected CAGR for the Bunya Virus Infection Market during the forecast period 2025 - 2035?

The expected CAGR for the Bunya Virus Infection Market during the forecast period 2025 - 2035 is 7.32%. Read More

Which companies are considered key players in the Bunya Virus Infection Market?

Key players in the Bunya Virus Infection Market include CSL Limited, Emergent BioSolutions, Takeda Pharmaceutical Company, Bavarian Nordic, Valneva SE, Vaxart, Inovio Pharmaceuticals, and AstraZeneca PLC. Read More

What are the main applications driving the Bunya Virus Infection Market?

The main applications driving the Bunya Virus Infection Market include Clinical Diagnosis, Research and Development, Vaccine Development, and Public Health Surveillance. Read More

What was the valuation of the Vaccine Development segment in 2024?

The valuation of the Vaccine Development segment in 2024 was between 100.0 and 250.0 USD Billion. Read More

How does the market segment for Hospitals compare to Diagnostic Laboratories in 2024?

In 2024, the Hospitals segment was valued between 123.61 and 276.09 USD Billion, while Diagnostic Laboratories were valued between 61.81 and 139.83 USD Billion. Read More

What is the projected growth for the Environmental transmission route segment by 2035?

The Environmental transmission route segment is projected to grow to between 149.02 and 312.18 USD Billion by 2035. Read More

What types of Bunya viruses are included in the market analysis?

The types of Bunya viruses included in the market analysis are Crimean-Congo Hemorrhagic Fever Virus, Hantavirus, Nairovirus, and Phlebovirus. Read More

What was the valuation range for the Zoonotic transmission route in 2024?

The valuation range for the Zoonotic transmission route in 2024 was between 80.0 and 180.0 USD Billion. Read More

Bunya Virus Infection Market

ID: MRFR/HC/33494-HCR

100 Pages

Rahul Gotadki

Last Updated: May 18, 2026

Bunya Virus Infection Market Research Report By Transmission Route (Vector-Borne, Airborne, Direct Contact), By Product Type (Vaccines, Antiviral Drugs, Diagnostic Tests), By End User (Hospitals, Diagnostic Laboratories, Research Institutions), By Treatment Method (Supportive Care, Antiviral Therapy, Immunotherapy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Clinical Diagnosis
  2. 4.1.2 Research and Development
  3. 4.1.3 Vaccine Development
  4. 4.1.4 Public Health Surveillance
2. 4.2 Healthcare, BY End Use (USD Billion)
  1. 4.2.1 Hospitals
  2. 4.2.2 Diagnostic Laboratories
  3. 4.2.3 Research Institutions
  4. 4.2.4 Government Health Agencies
3. 4.3 Healthcare, BY Transmission Route (USD Billion)
  1. 4.3.1 Vector-Borne
  2. 4.3.2 Zoonotic
  3. 4.3.3 Human-to-Human
  4. 4.3.4 Environmental
4. 4.4 Healthcare, BY Type of Bunya Virus (USD Billion)
  1. 4.4.1 Crimean-Congo Hemorrhagic Fever Virus
  2. 4.4.2 Hantavirus
  3. 4.4.3 Nairovirus
  4. 4.4.4 Phlebovirus
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 CSL Limited (AU)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Emergent BioSolutions (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Takeda Pharmaceutical Company Limited (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bavarian Nordic (DK)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Valneva SE (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Vaxart, Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Inovio Pharmaceuticals, Inc. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca PLC (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY END USE
5. 6.5 US MARKET ANALYSIS BY TRANSMISSION ROUTE
6. 6.6 US MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
7. 6.7 CANADA MARKET ANALYSIS BY APPLICATION
8. 6.8 CANADA MARKET ANALYSIS BY END USE
9. 6.9 CANADA MARKET ANALYSIS BY TRANSMISSION ROUTE
10. 6.10 CANADA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
13. 6.13 GERMANY MARKET ANALYSIS BY END USE
14. 6.14 GERMANY MARKET ANALYSIS BY TRANSMISSION ROUTE
15. 6.15 GERMANY MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
16. 6.16 UK MARKET ANALYSIS BY APPLICATION
17. 6.17 UK MARKET ANALYSIS BY END USE
18. 6.18 UK MARKET ANALYSIS BY TRANSMISSION ROUTE
19. 6.19 UK MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
20. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
21. 6.21 FRANCE MARKET ANALYSIS BY END USE
22. 6.22 FRANCE MARKET ANALYSIS BY TRANSMISSION ROUTE
23. 6.23 FRANCE MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
24. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
25. 6.25 RUSSIA MARKET ANALYSIS BY END USE
26. 6.26 RUSSIA MARKET ANALYSIS BY TRANSMISSION ROUTE
27. 6.27 RUSSIA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
28. 6.28 ITALY MARKET ANALYSIS BY APPLICATION
29. 6.29 ITALY MARKET ANALYSIS BY END USE
30. 6.30 ITALY MARKET ANALYSIS BY TRANSMISSION ROUTE
31. 6.31 ITALY MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
32. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
33. 6.33 SPAIN MARKET ANALYSIS BY END USE
34. 6.34 SPAIN MARKET ANALYSIS BY TRANSMISSION ROUTE
35. 6.35 SPAIN MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY END USE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY TRANSMISSION ROUTE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY APPLICATION
42. 6.42 CHINA MARKET ANALYSIS BY END USE
43. 6.43 CHINA MARKET ANALYSIS BY TRANSMISSION ROUTE
44. 6.44 CHINA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
45. 6.45 INDIA MARKET ANALYSIS BY APPLICATION
46. 6.46 INDIA MARKET ANALYSIS BY END USE
47. 6.47 INDIA MARKET ANALYSIS BY TRANSMISSION ROUTE
48. 6.48 INDIA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
49. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
50. 6.50 JAPAN MARKET ANALYSIS BY END USE
51. 6.51 JAPAN MARKET ANALYSIS BY TRANSMISSION ROUTE
52. 6.52 JAPAN MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY END USE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY TRANSMISSION ROUTE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
57. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
58. 6.58 MALAYSIA MARKET ANALYSIS BY END USE
59. 6.59 MALAYSIA MARKET ANALYSIS BY TRANSMISSION ROUTE
60. 6.60 MALAYSIA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
61. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
62. 6.62 THAILAND MARKET ANALYSIS BY END USE
63. 6.63 THAILAND MARKET ANALYSIS BY TRANSMISSION ROUTE
64. 6.64 THAILAND MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
65. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
66. 6.66 INDONESIA MARKET ANALYSIS BY END USE
67. 6.67 INDONESIA MARKET ANALYSIS BY TRANSMISSION ROUTE
68. 6.68 INDONESIA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
69. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
70. 6.70 REST OF APAC MARKET ANALYSIS BY END USE
71. 6.71 REST OF APAC MARKET ANALYSIS BY TRANSMISSION ROUTE
72. 6.72 REST OF APAC MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
75. 6.75 BRAZIL MARKET ANALYSIS BY END USE
76. 6.76 BRAZIL MARKET ANALYSIS BY TRANSMISSION ROUTE
77. 6.77 BRAZIL MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
78. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
79. 6.79 MEXICO MARKET ANALYSIS BY END USE
80. 6.80 MEXICO MARKET ANALYSIS BY TRANSMISSION ROUTE
81. 6.81 MEXICO MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
82. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
83. 6.83 ARGENTINA MARKET ANALYSIS BY END USE
84. 6.84 ARGENTINA MARKET ANALYSIS BY TRANSMISSION ROUTE
85. 6.85 ARGENTINA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TRANSMISSION ROUTE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY END USE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TRANSMISSION ROUTE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY END USE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TRANSMISSION ROUTE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
99. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
100. 6.100 REST OF MEA MARKET ANALYSIS BY END USE
101. 6.101 REST OF MEA MARKET ANALYSIS BY TRANSMISSION ROUTE
102. 6.102 REST OF MEA MARKET ANALYSIS BY TYPE OF BUNYA VIRUS
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY END USE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY TRANSMISSION ROUTE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY TRANSMISSION ROUTE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY TYPE OF BUNYA VIRUS, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY TYPE OF BUNYA VIRUS, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.2.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.2.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.3.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.3.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.3.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.4.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.4.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.4.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.5.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.5.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.5.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.6.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.6.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.6.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.7.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.7.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.7.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.8.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.8.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.8.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.9.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.9.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.9.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.10.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.10.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.10.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.11.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.11.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.11.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.12.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.12.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.12.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.13.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.13.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.13.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.14.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.14.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.14.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.15.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.15.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.15.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.16.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.16.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.16.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.17.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.17.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.17.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.18.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.18.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.18.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.19.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.19.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.19.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.20.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.20.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.20.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.21.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.21.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.21.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.22.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.22.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.22.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.23.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.23.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.23.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.24.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.24.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.24.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.25.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.25.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.25.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.26.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.26.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.26.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.27.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.27.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.27.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.28.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.28.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.28.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.29.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.29.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.29.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.30.2 BY END USE, 2025-2035 (USD Billion)
  3. 7.30.3 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
  4. 7.30.4 BY TYPE OF BUNYA VIRUS, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Bunya Virus Infection Market Segmentation

Bunya Virus Infection Market By Application (USD Billion, 2025-2035)

Clinical Diagnosis
Research and Development
Vaccine Development
Public Health Surveillance

Bunya Virus Infection Market By End Use (USD Billion, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutions
Government Health Agencies

Bunya Virus Infection Market By Transmission Route (USD Billion, 2025-2035)

Vector-Borne
Zoonotic
Human-to-Human
Environmental

Bunya Virus Infection Market By Type of Bunya Virus (USD Billion, 2025-2035)

Crimean-Congo Hemorrhagic Fever Virus
Hantavirus
Nairovirus
Phlebovirus

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”